Observational, Multicenter Study on the Efficacy, Tolerability, and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis Older than 80 Years

Conclusions: Nintedanib is effective and safe in patients with IPF aged #x3e;80 years, and no significant differences were found when clinical outcomes were compared with those of younger patients. Thus, older age should not be a barrier for the early prescription of antifibrotic treatment in IPF patients.Respiration
Source: Respiration - Category: Respiratory Medicine Source Type: research